The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
复制标题
循环肿瘤 DNA 和染色质修饰、治疗耐药和转移的相互作用
DOI：
10.1186/s12943-019-0989-z
复制
发表时间：
2019
期刊：
影响因子：
37.3
通讯作者：
Yu Fenglei
中科院分区：
文献类型：
--
作者：
Zhang Lei;Liang Yiyi;Li Shifu;Zeng Fanyuan;Meng Yongan;Chen Ziwei;Liu Shuang;Tao Yongguang;Yu Fenglei
外周循环游离DNA（cfDNA）是在血浆或血清流体中以无细胞状态检测到的DNA。对于癌症患者，cfDNA不仅来源于凋亡细胞，而且来源于坏死肿瘤细胞和在上皮-间充质转化期间逃逸到血液中的播散性肿瘤细胞。此外，来源于肿瘤的cfDNA，也称为循环肿瘤DNA（ctDNA），在癌症患者中携带肿瘤相关的遗传和表观遗传变化，这使得ctDNA成为各种癌症的肿瘤早期诊断、监测和治疗评估以及预后评估等的潜在生物标志物。此外，cfDNA染色质修饰的分析可以反映肿瘤的异质性，并具有预测肿瘤耐药性的潜力。
Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also from necrotic tumor cells and disseminated tumor cells that have escaped into the blood during epithelial-mesenchymal transition. Additionally, cfDNA derived from tumors, also known as circulating tumor DNA (ctDNA), carries tumor-associated genetic and epigenetic changes in cancer patients, which makes ctDNA a potential biomarker for the early diagnosis of tumors, monitory and therapeutic evaluations, and prognostic assessments, among others, for various kinds of cancer. Moreover, analyses of cfDNA chromatin modifications can reflect the heterogeneity of tumors and have potential for predicting tumor drug resistance.